CRESCENT BIOPHARMA, INC. (CBIO)
About CRESCENT BIOPHARMA, INC.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $10.8M
- Net income
- -$153.9M
- Total assets
- $240.3M
- Market cap
- $496.3M
- Operating margin
- -1407.5%
- Net margin
- -1419.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $10.8M
- Operating expenses
- $163.5M
- Operating income
- -$152.6M
- Income tax
- $2.0M
- Net income
- -$153.9M
Balance sheet
- Total assets
- $240.3M
- Current assets
- $236.7M
- Total liabilities
- $37.3M
- Current liabilities
- $36.1M
- Shareholders’ equity
- $203.0M
Cash flow
- Operating cash flow
- -$71.5M
- Investing cash flow
- -$72.9M
- Financing cash flow
- $323.0M
- Net cash flow
- $178.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $496.3M
- Shares outstanding
- 30.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 16, 2025
Crescent Biopharma, Inc. (CBIO) Stock Price
- Reported a net loss of $153.9M in FY2025.
- Trading 40% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CRESCENT BIOPHARMA, INC..
Write a review
News about CRESCENT BIOPHARMA, INC.
News & sentiment via Polygon.io
Crescent Biopharma, Inc.: frequently asked questions
Is Crescent Biopharma, Inc. an American company?
Crescent Biopharma, Inc. is a US-based company headquartered in Waltham, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Crescent Biopharma, Inc. headquartered?
Crescent Biopharma, Inc. is headquartered in Waltham, Massachusetts, United States.
Is Crescent Biopharma, Inc. publicly traded?
Yes — Crescent Biopharma, Inc. is a publicly traded company. Its stock trades under the ticker symbol CBIO on the NASDAQ.
What does Crescent Biopharma, Inc. do?
Crescent Biopharma, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
